Cell death biotech Kojin winds down, citing 4 funding challenges

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.

The cancer- and autoimmune-focused company will wind down operations over the next few months, according to a LinkedIn status from the business posted on Feb. 13. The biotech had hoped to use iron-dependent cell death, also known as ferroptosis, to treat drug-resistant cancer and other conditions.